GOODWILL(SH:688246) Xin Lang Cai Jing·2025-12-24 01:36Group 1 - The core viewpoint of the news is that 嘉和美康 experienced a significant decline in stock price and financial performance, indicating potential challenges for the company [1][2]. Group 2 - On December 23, 嘉和美康's stock price dropped by 5.15%, with a trading volume of 145 million yuan. The financing data showed a net financing outflow of 770,700 yuan for the day [1]. - As of December 23, 嘉和美康's total margin trading balance was 187 million yuan, accounting for 5.55% of its market capitalization, which is above the 80th percentile of the past year [1]. - The company had no short selling activity on December 23, with a short selling balance of 331,000 yuan, also above the 90th percentile of the past year [1]. - 嘉和美康's main business includes medical information software development and commercialization, with revenue composition being 42.39% from software development and technical services, 37.64% from self-developed software sales, and 19.86% from purchased software and hardware sales [1]. Group 3 - As of November 10, 嘉和美康 had 8,866 shareholders, an increase of 16.78%, while the average circulating shares per person decreased by 14.37% [2]. - For the period from January to September 2025, 嘉和美康 reported a revenue of 330 million yuan, a year-on-year decrease of 30.67%, and a net profit attributable to shareholders of -174 million yuan, a year-on-year decrease of 320.68% [2]. - Among the top ten circulating shareholders as of September 30, 2025, 长城消费增值混合A held 2.001 million shares, a decrease of 410,000 shares compared to the previous period [2].